Cancer Research and Treatment10.4143/crt.2018.2622019512727-736Early Decline in Left Ventricular Ejection Fraction Can Predict Trastuzumab-Related Cardiotoxicity in Patients with Breast Cancer: A Study Using 13 Years of Registry DataEun Kyoung Kim, Jinhyun Cho, Ji-Yeon Kim, Sung-A Chang, Sung-Ji Park, Jin Oh Choi, Sang Chol Lee, Jin Seok Ahn, Seung Woo Park, Young-Hyuck Im, Eun Seok Jeon, Yeon Hee Park,,
Annals of Oncology10.1093/annonc/mdx655.006201728x17-x18Early drop of LV ejection fraction can predict trastuzumab-related cardiotoxicity in patients with breast cancerJ. Cho, E.K. Kim, K.H. Yoo, H. Lee, H.K. Kim, M.H. Heo, J. Park, J.S. Ahn, Y-H Im, Y.H. Park,,
Reactions Weekly10.1007/s40278-017-38797-420171679172-72Epirubicin/trastuzumab,,
British Journal of Cancer10.1038/sj.bjc.6600346200286111697-1700Early decline in left ventricular ejection fraction predicts doxorubicin cardiotoxicity in lymphoma patientsT Nousiainen, E Jantunen, E Vanninen, J Hartikainen,,
Value in Health10.1016/j.jval.2014.08.1302014177A739Change in Percentage of Left Ventricular Ejection Fraction in Breast Cancer Patients Received Trastuzumab TreatmentN Areepium,
European Heart Journal10.1093/eurheartj/ehz746.0838201940Supplement_1P6237Clinical utility of echocardiographic left-ventricular ejection fraction monitoring for cardiotoxicity risk assessment in patients with HER2+ early breast cancer undergoing trastuzumab-based therapyF Posch, T Glantschnig, S Firla, M Smolle, M Balic, F Moik, H Stoeger, A Zirlik, M Pichler, P Rainer,
Annals of Oncology10.1093/annonc/mdy300.030201829viii613Left ventricular ejection fraction (LVEF) change for the first 6 months predicts development of trastuzumab-related cardiotoxicity in patients with breast cancer: An implication for the more efficient cardiac surveillanceJ.H. Yeo, H. Ahn, I. Park, Y.S. Kim, S.J. Sym, E.K. Cho, D.B. Shin,,
Reactions Weekly10.1007/s40278-014-5210-y201415281203-203Trastuzumab,,
Reactions Weekly10.1007/s40278-015-4134-5201515631205-205Trastuzumab,,
Reactions Weekly10.1007/s40278-020-76500-x202017961214-214Trastuzumab,,